Literature DB >> 14617298

Pulmonary involvement during cytomegalovirus infection in immunosuppressed patients.

E F de Maar1, E A M Verschuuren, M C Harmsen, T H The, W J van Son.   

Abstract

Although cytomegalovirus (CMV) pulmonary involvement after solid organ transplantation is infrequently seen nowadays, CMV pneumonitis is still a potential lethal complication. Introduction of the pp65 antigenemia assay enabled early and rapid diagnosis of CMV viremia in transplant patients prior to symptoms. Also, in asymptomatic patients with CMV viremia, a decreased pulmonary diffusion capacity could be demonstrated. In this review, we discuss clinical and subclinical pulmonary involvement of CMV infection in the immunocompromised host with an emphasis on transplant recipients. The clinical course, diagnosis, therapy, prophylaxis, and pathophysiology of CMV pneumonitis are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14617298     DOI: 10.1034/j.1399-3062.2003.00023.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  3 in total

1.  Influence of sphingosine-1-phosphate signaling on HCMV replication in human embryonal lung fibroblasts.

Authors:  Anika Zilch; Christian Rien; Cynthia Weigel; Stefanie Huskobla; Brigitte Glück; Katrin Spengler; Andreas Sauerbrei; Regine Heller; Markus Gräler; Andreas Henke
Journal:  Med Microbiol Immunol       Date:  2018-04-26       Impact factor: 3.402

Review 2.  Cytomegalovirus pneumonia in hematopoietic stem cell recipients.

Authors:  Giovanna Travi; Steven A Pergam
Journal:  J Intensive Care Med       Date:  2013-02-06       Impact factor: 3.510

3.  Effects of intrapulmonary viral tropism and cytokine expression on the histological patterns of cytomegalovirus pneumonia.

Authors:  Yoshifumi Arai; Takashi Tsuchida; Isao Kosugi; Hideya Kawasaki; Shiori Meguro; Mana Kinoshita; Satoshi Baba; Matsuyoshi Maeda; Yuichiro Shinmura; Yoshihiro Tsutsui; Toshihide Iwashita
Journal:  Pathol Int       Date:  2012-09       Impact factor: 2.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.